DAWN
Day One Biopharmaceuticals, Inc.$21.50+0.01 (+0.02%)Prev Close$21.49·MCap$2.22B·P/E—·Vol605.9K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
22
$1.45M
◆
Net Activity
Net Seller
$1.45M
●
Active Insiders
5
last 12 mo
Over the past 12 months, insider activity at Day One Biopharmaceuticals, Inc. (DAWN) has been exclusively selling, with 0 insider purchases totaling $0.00 and 22 insider sales totaling $1.45M. The most recent insider transaction was by Bender Jeremy (director, officer: CHIEF EXECUTIVE OFFICER), who sold $179.3K worth of shares on Feb 18, 2026. Day One Biopharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.22B.
DAWN Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | Bender Jeremy | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 15,459 | $11.60 | $179.3K | 204,603 |
| Feb 18, 2026 | Dubow Adam | officer: Gen Counsel & Secretary | Sell | 6,395 | $11.60 | $74.2K | 72,694 |
| Feb 18, 2026 | Merendino Lauren | officer: Chief Commercial Officer | Sell | 5,814 | $11.60 | $67.4K | 60,157 |
| Feb 18, 2026 | VASCONCELLES MICHAEL | officer: Head of Research and Dev. | Sell | 2,728 | $11.60 | $31.6K | 4,397-38% |
| Feb 18, 2026 | York Charles N II | officer: COO and CFO | Sell | 6,065 | $11.60 | $70.4K | 312,025 |
| Feb 15, 2026 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 15,459 | $11.60 | $179.3K | 0 |
| Feb 15, 2026 | Dubow Adam | Gen Counsel & Secretary | Sell | 6,395 | $11.60 | $74.2K | 0 |
| Feb 15, 2026 | Merendino Lauren | Chief Commercial Officer | Sell | 5,814 | $11.60 | $67.4K | 0 |
| Feb 15, 2026 | VASCONCELLES MICHAEL | Head of Research and Dev. | Sell | 2,728 | $11.60 | $31.6K | 0 |
| Feb 15, 2026 | York Charles N II | COO and CFO | Sell | 6,065 | $11.60 | $70.4K | 0 |
| Nov 15, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 15,894 | $8.91 | $141.7K | 0 |
| Nov 15, 2025 | Dubow Adam | Gen Counsel & Secretary | Sell | 4,319 | $8.91 | $38.5K | 0 |
| Nov 15, 2025 | Merendino Lauren | Chief Commercial Officer | Sell | 3,726 | $8.91 | $33.2K | 0 |
| Nov 15, 2025 | York Charles N II | COO and CFO | Sell | 4,062 | $8.91 | $36.2K | 0 |
| Aug 15, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 16,058 | $6.77 | $108.7K | 0 |
| Aug 15, 2025 | Dubow Adam | Gen Counsel & Secretary | Sell | 4,365 | $6.77 | $29.5K | 0 |
| Aug 15, 2025 | Merendino Lauren | Chief Commercial Officer | Sell | 3,766 | $6.77 | $25.5K | 0 |
| Aug 15, 2025 | York Charles N II | COO and CFO | Sell | 4,106 | $6.77 | $27.8K | 0 |
| May 15, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 13,964 | $6.26 | $87.4K | 0 |
| May 15, 2025 | Dubow Adam | GENERAL COUNSEL | Sell | 4,552 | $6.26 | $28.5K | 0 |
| May 15, 2025 | Merendino Lauren | Chief Commercial Officer | Sell | 3,927 | $6.26 | $24.6K | 0 |
| May 15, 2025 | York Charles N II | COO, CFO AND SECRETARY | Sell | 4,282 | $6.26 | $26.8K | 0 |
| Feb 15, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 12,048 | $11.96 | $144.1K | 0 |
| Feb 15, 2025 | Dubow Adam | GENERAL COUNSEL | Sell | 4,646 | $11.96 | $55.6K | 0 |
| Feb 15, 2025 | York Charles N II | COO, CFO AND SECRETARY | Sell | 4,370 | $11.96 | $52.3K | 0 |
| Dec 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 30,000 | $13.31 | $399.3K | 0 |
| Nov 15, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 10,554 | $13.21 | $139.4K | 0 |
| Nov 15, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 2,206 | $13.21 | $29.1K | 0 |
| Nov 15, 2024 | Dubow Adam | GENERAL COUNSEL | Sell | 3,165 | $13.21 | $41.8K | 0 |
| Nov 15, 2024 | York Charles N II | COO, CFO AND SECRETARY | Sell | 2,602 | $13.21 | $34.4K | 0 |
| Nov 8, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 28,255 | $16.15 | $456.2K | 0 |
| Nov 7, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 11,245 | $16.03 | $180.3K | 0 |
| Oct 31, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 500 | $16.02 | $8.0K | 0 |
| Sep 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 30,000 | $14.22 | $426.7K | 0 |
| Aug 15, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 10,681 | $14.00 | $149.5K | 0 |
| Aug 15, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 2,232 | $14.00 | $31.2K | 0 |
| Aug 15, 2024 | Dubow Adam | GENERAL COUNSEL | Sell | 3,202 | $14.00 | $44.8K | 0 |
| Aug 15, 2024 | York Charles N II | COO, CFO AND SECRETARY | Sell | 2,633 | $14.00 | $36.9K | 0 |
| Jul 16, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 20,000 | $16.01 | $320.2K | 0 |
| Jun 21, 2024 | Ramasastry Saira | Director | Sell | 10,000 | $13.19 | $131.9K | 0 |
| Jun 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 30,000 | $12.62 | $378.6K | 0 |
| May 15, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 7,873 | $16.08 | $126.6K | 0 |
| May 15, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 2,267 | $16.08 | $36.5K | 0 |
| May 15, 2024 | Dubow Adam | GENERAL COUNSEL | Sell | 3,253 | $16.08 | $52.3K | 0 |
| May 15, 2024 | York Charles N II | COO, CFO AND SECRETARY | Sell | 2,675 | $16.08 | $43.0K | 0 |
| May 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 10,000 | $16.37 | $163.7K | 0 |
| May 1, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 79,211 | $17.87 | $1.42M | 0 |
| May 1, 2024 | York Charles N II | COO, CFO AND SECRETARY | Sell | 60,461 | $17.88 | $1.08M | 0 |
| Apr 18, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 10,000 | $16.02 | $160.2K | 0 |
| Mar 25, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 10,000 | $16.01 | $160.1K | 0 |
Showing 1–50 of 129
1 / 3
DAWN Insider Buying Activity
The following table shows recent insider purchases of Day One Biopharmaceuticals, Inc. (DAWN) stock reported via SEC Form 4 filings.
No insider buying activity found for DAWN in the last 12 months.
DAWN Insider Selling Activity
The following table shows recent insider sales of Day One Biopharmaceuticals, Inc. (DAWN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | Bender Jeremy | director, officer: CHIEF EXECUTIVE OFFICER | Sell | 15,459 | $11.60 | $179.3K | 204,603 |
| Feb 18, 2026 | Dubow Adam | officer: Gen Counsel & Secretary | Sell | 6,395 | $11.60 | $74.2K | 72,694 |
| Feb 18, 2026 | Merendino Lauren | officer: Chief Commercial Officer | Sell | 5,814 | $11.60 | $67.4K | 60,157 |
| Feb 18, 2026 | VASCONCELLES MICHAEL | officer: Head of Research and Dev. | Sell | 2,728 | $11.60 | $31.6K | 4,397-38% |
| Feb 18, 2026 | York Charles N II | officer: COO and CFO | Sell | 6,065 | $11.60 | $70.4K | 312,025 |
| Feb 15, 2026 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 15,459 | $11.60 | $179.3K | 0 |
| Feb 15, 2026 | Dubow Adam | Gen Counsel & Secretary | Sell | 6,395 | $11.60 | $74.2K | 0 |
| Feb 15, 2026 | Merendino Lauren | Chief Commercial Officer | Sell | 5,814 | $11.60 | $67.4K | 0 |
| Feb 15, 2026 | VASCONCELLES MICHAEL | Head of Research and Dev. | Sell | 2,728 | $11.60 | $31.6K | 0 |
| Feb 15, 2026 | York Charles N II | COO and CFO | Sell | 6,065 | $11.60 | $70.4K | 0 |
| Nov 15, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 15,894 | $8.91 | $141.7K | 0 |
| Nov 15, 2025 | Dubow Adam | Gen Counsel & Secretary | Sell | 4,319 | $8.91 | $38.5K | 0 |
| Nov 15, 2025 | Merendino Lauren | Chief Commercial Officer | Sell | 3,726 | $8.91 | $33.2K | 0 |
| Nov 15, 2025 | York Charles N II | COO and CFO | Sell | 4,062 | $8.91 | $36.2K | 0 |
| Aug 15, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 16,058 | $6.77 | $108.7K | 0 |
| Aug 15, 2025 | Dubow Adam | Gen Counsel & Secretary | Sell | 4,365 | $6.77 | $29.5K | 0 |
| Aug 15, 2025 | Merendino Lauren | Chief Commercial Officer | Sell | 3,766 | $6.77 | $25.5K | 0 |
| Aug 15, 2025 | York Charles N II | COO and CFO | Sell | 4,106 | $6.77 | $27.8K | 0 |
| May 15, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 13,964 | $6.26 | $87.4K | 0 |
| May 15, 2025 | Dubow Adam | GENERAL COUNSEL | Sell | 4,552 | $6.26 | $28.5K | 0 |
| May 15, 2025 | Merendino Lauren | Chief Commercial Officer | Sell | 3,927 | $6.26 | $24.6K | 0 |
| May 15, 2025 | York Charles N II | COO, CFO AND SECRETARY | Sell | 4,282 | $6.26 | $26.8K | 0 |
| Feb 15, 2025 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 12,048 | $11.96 | $144.1K | 0 |
| Feb 15, 2025 | Dubow Adam | GENERAL COUNSEL | Sell | 4,646 | $11.96 | $55.6K | 0 |
| Feb 15, 2025 | York Charles N II | COO, CFO AND SECRETARY | Sell | 4,370 | $11.96 | $52.3K | 0 |
| Dec 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 30,000 | $13.31 | $399.3K | 0 |
| Nov 15, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 10,554 | $13.21 | $139.4K | 0 |
| Nov 15, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 2,206 | $13.21 | $29.1K | 0 |
| Nov 15, 2024 | Dubow Adam | GENERAL COUNSEL | Sell | 3,165 | $13.21 | $41.8K | 0 |
| Nov 15, 2024 | York Charles N II | COO, CFO AND SECRETARY | Sell | 2,602 | $13.21 | $34.4K | 0 |
| Nov 8, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 28,255 | $16.15 | $456.2K | 0 |
| Nov 7, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 11,245 | $16.03 | $180.3K | 0 |
| Oct 31, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 500 | $16.02 | $8.0K | 0 |
| Sep 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 30,000 | $14.22 | $426.7K | 0 |
| Aug 15, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 10,681 | $14.00 | $149.5K | 0 |
| Aug 15, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 2,232 | $14.00 | $31.2K | 0 |
| Aug 15, 2024 | Dubow Adam | GENERAL COUNSEL | Sell | 3,202 | $14.00 | $44.8K | 0 |
| Aug 15, 2024 | York Charles N II | COO, CFO AND SECRETARY | Sell | 2,633 | $14.00 | $36.9K | 0 |
| Jul 16, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 20,000 | $16.01 | $320.2K | 0 |
| Jun 21, 2024 | Ramasastry Saira | Director | Sell | 10,000 | $13.19 | $131.9K | 0 |
| Jun 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 30,000 | $12.62 | $378.6K | 0 |
| May 15, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 7,873 | $16.08 | $126.6K | 0 |
| May 15, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 2,267 | $16.08 | $36.5K | 0 |
| May 15, 2024 | Dubow Adam | GENERAL COUNSEL | Sell | 3,253 | $16.08 | $52.3K | 0 |
| May 15, 2024 | York Charles N II | COO, CFO AND SECRETARY | Sell | 2,675 | $16.08 | $43.0K | 0 |
| May 10, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 10,000 | $16.37 | $163.7K | 0 |
| May 1, 2024 | Bender Jeremy | CHIEF EXECUTIVE OFFICER | Sell | 79,211 | $17.87 | $1.42M | 0 |
| May 1, 2024 | York Charles N II | COO, CFO AND SECRETARY | Sell | 60,461 | $17.88 | $1.08M | 0 |
| Apr 18, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 10,000 | $16.02 | $160.2K | 0 |
| Mar 25, 2024 | Blackman Samuel C. | HEAD OF R&D | Sell | 10,000 | $16.01 | $160.1K | 0 |
DAWN Insiders
Similar Stocks to DAWN
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B